Breaking News, Collaborations & Alliances

ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases

Research will focus on Sigma1 dysfunction associated with early onset diseases, such as ALS and Alzheimer's

ChemDiv Inc., a fully integrated CRO, has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases. Under the agreement, ChemDiv grants Context access to its integrated discovery platform, while Torrey Pines will invest in Context and provide network resources to support pre-commercial R&D.   This collaboration wil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters